ACRUX LIMITED - Announcements

Market Cap $15.11M Add to my watchlist

Healthcare

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is... Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ACR	Appendix 4G and Corporate Governance Statement		26/08/22	497.87KB	Share
ACR	Appendix 4E and FY22 Annual Report	PRICE SENSITIVE	26/08/22	7.47MB	Share
ACR	Acrux's sixth generic dossier accepted by FDA for review	PRICE SENSITIVE	08/08/22	153.25KB	Share
ACR	Updated Corporate Policy - Code of Conduct		28/06/22	202.78KB	Share
ACR	Appendix 3Y - Oldham		22/06/22	255.84KB	Share
ACR	Application for quotation of securities - ACR		22/06/22	26.16KB	Share
ACR	Acrux announces commercial agreement with Padagis	PRICE SENSITIVE	20/06/22	149.19KB	Share
ACR	Successful patent litigation outcome	PRICE SENSITIVE	30/05/22	172.29KB	Share
ACR	Appendix 3Y - Brumley		23/05/22	254.67KB	Share
ACR	Appendix 3Y - Dobinson		23/05/22	213.75KB	Share
ACR	Application for quotation of securities - ACR		23/05/22	26.14KB	Share
ACR	Notification of cessation of securities - ACR		14/04/22	21.43KB	Share
ACR	Application for quotation of securities - ACR		14/04/22	25.75KB	Share
ACR	Appendix 3Y - Brumley		16/03/22	263.81KB	Share
ACR	Application for quotation of securities - ACR		16/03/22	26.1KB	Share
ACR	Updated Continuous Disclosure & Shareholder Reporting Policy		25/02/22	174.94KB	Share
ACR	Updated Board Charter		25/02/22	237.98KB	Share
ACR	Appendix 3Y - Ross Dobinson		25/02/22	214.5KB	Share
ACR	Application for quotation of securities - ACR		25/02/22	24.26KB	Share
ACR	Appendix 4D, Half Year Accounts as at 31 December 2021	PRICE SENSITIVE	24/02/22	618.71KB	Share
ACR	Notification of cessation of securities - ACR		10/02/22	21.44KB	Share
ACR	Notification regarding unquoted securities - ACR		10/02/22	25.89KB	Share
ACR	Application for quotation of securities - ACR		10/02/22	25.73KB	Share
ACR	Securities Trading Policy		17/12/21	197.23KB	Share
ACR	Whistleblower Policy		17/12/21	251.32KB	Share
ACR	Appendix 3Y Brumley		29/11/21	255.13KB	Share
ACR	Appendix 3Y Kotsanis		26/11/21	268.01KB	Share
ACR	Appendix 3Y Brumley		26/11/21	254.85KB	Share
ACR	Notification regarding unquoted securities - ACR		26/11/21	25.11KB	Share
ACR	Notification of cessation of securities - ACR		26/11/21	21.52KB	Share
ACR	Amendment to Constitution		26/11/21	595.52KB	Share
ACR	Results of Annual General Meeting		23/11/21	126.68KB	Share
ACR	Annual General Meeting Presentation and Addresses		23/11/21	1.43MB	Share
ACR	R&D Tax Incentive Rebate received		11/11/21	112.11KB	Share
ACR	Anti-Bribery, Corruption and Fraud Policy		04/11/21	251.17KB	Share
ACR	JobKeeper disclosure		22/10/21	34.07KB	Share
ACR	Annual Report to shareholders		22/10/21	1.04MB	Share
ACR	Notice of Annual General Meeting/Proxy Form		22/10/21	1.99MB	Share
ACR	Application for quotation of securities - ACR		15/10/21	26.04KB	Share
ACR	Acrux and Harris terminate license agreement	PRICE SENSITIVE	11/10/21	128.38KB	Share
ACR	Annual General meeting and date for director nominations		27/09/21	110.49KB	Share
ACR	Appendix 3Y - Ross Dobinson		15/09/21	206.54KB	Share
ACR	Application for quotation of securities - ACR		15/09/21	24.25KB	Share
ACR	Acrux's fifth generic dossier accepted by FDA for review	PRICE SENSITIVE	13/09/21	193.42KB	Share
ACR	Acrux Investor Presentation - September 2021	PRICE SENSITIVE	02/09/21	947.81KB	Share
ACR	US Launch - Testosterone Topical Solution	PRICE SENSITIVE	26/08/21	201.45KB	Share
ACR	Appendix 4G and Corporate Governance Statement		25/08/21	516.73KB	Share
ACR	Appendix 4E and Financial Report	PRICE SENSITIVE	25/08/21	1.15MB	Share
ACR	Acrux receives third FDA ANDA approval	PRICE SENSITIVE	28/07/21	165.58KB	Share
ACR	Notification of cessation of securities - ACR		30/06/21	21.38KB	Share
ACR	Audit and Risk Committee Charter		24/06/21	259.71KB	Share
ACR	Human Capital and Nomination Committee Charter		24/06/21	211.16KB	Share
ACR	Code of Conduct		24/06/21	190.97KB	Share
ACR	Acrux Receives FDA Approval - Generic Efinaconazole Solution	PRICE SENSITIVE	22/06/21	193.2KB	Share
ACR	Notification of cessation of securities - ACR		21/06/21	21.38KB	Share
ACR	Change in Company Secretary		21/06/21	127.86KB	Share
ACR	Change of Director's Interest Notice - Ross Dobinson		17/06/21	216.39KB	Share
ACR	Application for quotation of securities - ACR		17/06/21	27.07KB	Share
ACR	Acrux confirms patent challenge	PRICE SENSITIVE	08/06/21	221.62KB	Share
ACR	Final Director's Interest Notice - amended		04/06/21	335.28KB	Share
ACR	Final Director's Interest Notice - Mr Norman Gray		04/06/21	215.64KB	Share
ACR	Initial Director's Interest Notice - Mr Don Brumley		04/06/21	255.21KB	Share
ACR	Acrux Limited Announces Board Appointment		04/06/21	130.1KB	Share
ACR	R&D Tax Incentive Rebate - Overseas Finding Application		31/05/21	135.4KB	Share
ACR	Appendix 2A		18/05/21	336.02KB	Share
ACR	R&D Tax Incentive Rebate - Overseas Finding Application		30/04/21	136.19KB	Share
ACR	Appendix 2A		15/04/21	335.65KB	Share
ACR	Acrux's fourth generic dossier accepted by FDA for review	PRICE SENSITIVE	15/04/21	241.93KB	Share
ACR	Change of Director's Interest Notice - Ross Dobinson		15/03/21	215.92KB	Share
ACR	Appendix 2A		15/03/21	338.88KB	Share
ACR	Acrux Investor Presentation	PRICE SENSITIVE	25/02/21	1.04MB	Share
ACR	Appendix 4D and Half Year Accounts - for the 31 Dec ac	PRICE SENSITIVE	25/02/21	1.66MB	Share
ACR	Appendix 2A		15/02/21	336.83KB	Share
ACR	Amended Appendix 3Y - Geoff Brooke		05/02/21	252.24KB	Share
ACR	Appendix 2A		04/02/21	474.08KB	Share
ACR	Appendix 3G		04/02/21	495.57KB	Share
ACR	Change of Director's Interest Notice		04/02/21	633.49KB	Share
ACR	Cleansing Statement		04/02/21	125.57KB	Share
ACR	Appendix 2A		03/02/21	327.52KB	Share
ACR	Appendix 2A - Share Purchase Plan		02/02/21	327.37KB	Share
ACR	Share Purchase Plan Closes Oversubscribed	PRICE SENSITIVE	02/02/21	179.96KB	Share
ACR	Results of Extraordinary General Meeting		28/01/21	163.16KB	Share
ACR	Change of Director's Interest Notice		15/01/21	249.39KB	Share
ACR	Appendix 2A		15/01/21	333.35KB	Share
ACR	Acrux Receives FDA Approval - Generic Testosterone Solution	PRICE SENSITIVE	12/01/21	155.5KB	Share
ACR	Acrux Ltd Share Purchase Plan Offer Booklet	PRICE SENSITIVE	08/01/21	823.79KB	Share
ACR	Ceasing to be a substantial holder		30/12/20	143.27KB	Share
ACR	Ceasing to be a substantial holder		29/12/20	135.55KB	Share
ACR	Becoming a substantial holder		29/12/20	665.4KB	Share
ACR	Cleansing Notice		24/12/20	137.71KB	Share
ACR	EGM - Virtual Meeting Online Guide		23/12/20	275.83KB	Share
ACR	Notice of Extraordinary General Meeting/Proxy Form		23/12/20	508.15KB	Share
ACR	Appendix 2A		23/12/20	326.57KB	Share
ACR	Proposed issue of Securities - ACR		21/12/20	24.81KB	Share
ACR	Proposed issue of Securities - ACR		21/12/20	34.05KB	Share
ACR	Acrux Raises $7.8m Via Placement and Announces SPP	PRICE SENSITIVE	21/12/20	203.34KB	Share
ACR	Trading Halt	PRICE SENSITIVE	17/12/20	183.82KB	Share
ACR	Change of Director's Interest Notice		15/12/20	251.41KB	Share
ACR	Appendix 2A		15/12/20	334.52KB	Share
ACR	Change of Director's Interest Notice		17/11/20	344.96KB	Share

ACR Appendix 4G and Corporate Governance Statement
26/08/22		497.87KB	Share
ACR Appendix 4E and FY22 Annual Report
26/08/22	PRICE SENSITIVE	7.47MB	Share
ACR Acrux's sixth generic dossier accepted by FDA for review
08/08/22	PRICE SENSITIVE	153.25KB	Share
ACR Updated Corporate Policy - Code of Conduct
28/06/22		202.78KB	Share
ACR Appendix 3Y - Oldham
22/06/22		255.84KB	Share
ACR Application for quotation of securities - ACR
22/06/22		26.16KB	Share
ACR Acrux announces commercial agreement with Padagis
20/06/22	PRICE SENSITIVE	149.19KB	Share
ACR Successful patent litigation outcome
30/05/22	PRICE SENSITIVE	172.29KB	Share
ACR Appendix 3Y - Brumley
23/05/22		254.67KB	Share
ACR Appendix 3Y - Dobinson
23/05/22		213.75KB	Share
ACR Application for quotation of securities - ACR
23/05/22		26.14KB	Share
ACR Notification of cessation of securities - ACR
14/04/22		21.43KB	Share
ACR Application for quotation of securities - ACR
14/04/22		25.75KB	Share
ACR Appendix 3Y - Brumley
16/03/22		263.81KB	Share
ACR Application for quotation of securities - ACR
16/03/22		26.1KB	Share
ACR Updated Continuous Disclosure & Shareholder Reporting Policy
25/02/22		174.94KB	Share
ACR Updated Board Charter
25/02/22		237.98KB	Share
ACR Appendix 3Y - Ross Dobinson
25/02/22		214.5KB	Share
ACR Application for quotation of securities - ACR
25/02/22		24.26KB	Share
ACR Appendix 4D, Half Year Accounts as at 31 December 2021
24/02/22	PRICE SENSITIVE	618.71KB	Share
ACR Notification of cessation of securities - ACR
10/02/22		21.44KB	Share
ACR Notification regarding unquoted securities - ACR
10/02/22		25.89KB	Share
ACR Application for quotation of securities - ACR
10/02/22		25.73KB	Share
ACR Securities Trading Policy
17/12/21		197.23KB	Share
ACR Whistleblower Policy
17/12/21		251.32KB	Share
ACR Appendix 3Y Brumley
29/11/21		255.13KB	Share
ACR Appendix 3Y Kotsanis
26/11/21		268.01KB	Share
ACR Appendix 3Y Brumley
26/11/21		254.85KB	Share
ACR Notification regarding unquoted securities - ACR
26/11/21		25.11KB	Share
ACR Notification of cessation of securities - ACR
26/11/21		21.52KB	Share
ACR Amendment to Constitution
26/11/21		595.52KB	Share
ACR Results of Annual General Meeting
23/11/21		126.68KB	Share
ACR Annual General Meeting Presentation and Addresses
23/11/21		1.43MB	Share
ACR R&D Tax Incentive Rebate received
11/11/21		112.11KB	Share
ACR Anti-Bribery, Corruption and Fraud Policy
04/11/21		251.17KB	Share
ACR JobKeeper disclosure
22/10/21		34.07KB	Share
ACR Annual Report to shareholders
22/10/21		1.04MB	Share
ACR Notice of Annual General Meeting/Proxy Form
22/10/21		1.99MB	Share
ACR Application for quotation of securities - ACR
15/10/21		26.04KB	Share
ACR Acrux and Harris terminate license agreement
11/10/21	PRICE SENSITIVE	128.38KB	Share
ACR Annual General meeting and date for director nominations
27/09/21		110.49KB	Share
ACR Appendix 3Y - Ross Dobinson
15/09/21		206.54KB	Share
ACR Application for quotation of securities - ACR
15/09/21		24.25KB	Share
ACR Acrux's fifth generic dossier accepted by FDA for review
13/09/21	PRICE SENSITIVE	193.42KB	Share
ACR Acrux Investor Presentation - September 2021
02/09/21	PRICE SENSITIVE	947.81KB	Share
ACR US Launch - Testosterone Topical Solution
26/08/21	PRICE SENSITIVE	201.45KB	Share
ACR Appendix 4G and Corporate Governance Statement
25/08/21		516.73KB	Share
ACR Appendix 4E and Financial Report
25/08/21	PRICE SENSITIVE	1.15MB	Share
ACR Acrux receives third FDA ANDA approval
28/07/21	PRICE SENSITIVE	165.58KB	Share
ACR Notification of cessation of securities - ACR
30/06/21		21.38KB	Share
ACR Audit and Risk Committee Charter
24/06/21		259.71KB	Share
ACR Human Capital and Nomination Committee Charter
24/06/21		211.16KB	Share
ACR Code of Conduct
24/06/21		190.97KB	Share
ACR Acrux Receives FDA Approval - Generic Efinaconazole Solution
22/06/21	PRICE SENSITIVE	193.2KB	Share
ACR Notification of cessation of securities - ACR
21/06/21		21.38KB	Share
ACR Change in Company Secretary
21/06/21		127.86KB	Share
ACR Change of Director's Interest Notice - Ross Dobinson
17/06/21		216.39KB	Share
ACR Application for quotation of securities - ACR
17/06/21		27.07KB	Share
ACR Acrux confirms patent challenge
08/06/21	PRICE SENSITIVE	221.62KB	Share
ACR Final Director's Interest Notice - amended
04/06/21		335.28KB	Share
ACR Final Director's Interest Notice - Mr Norman Gray
04/06/21		215.64KB	Share
ACR Initial Director's Interest Notice - Mr Don Brumley
04/06/21		255.21KB	Share
ACR Acrux Limited Announces Board Appointment
04/06/21		130.1KB	Share
ACR R&D Tax Incentive Rebate - Overseas Finding Application
31/05/21		135.4KB	Share
ACR Appendix 2A
18/05/21		336.02KB	Share
ACR R&D Tax Incentive Rebate - Overseas Finding Application
30/04/21		136.19KB	Share
ACR Appendix 2A
15/04/21		335.65KB	Share
ACR Acrux's fourth generic dossier accepted by FDA for review
15/04/21	PRICE SENSITIVE	241.93KB	Share
ACR Change of Director's Interest Notice - Ross Dobinson
15/03/21		215.92KB	Share
ACR Appendix 2A
15/03/21		338.88KB	Share
ACR Acrux Investor Presentation
25/02/21	PRICE SENSITIVE	1.04MB	Share
ACR Appendix 4D and Half Year Accounts - for the 31 Dec ac
25/02/21	PRICE SENSITIVE	1.66MB	Share
ACR Appendix 2A
15/02/21		336.83KB	Share
ACR Amended Appendix 3Y - Geoff Brooke
05/02/21		252.24KB	Share
ACR Appendix 2A
04/02/21		474.08KB	Share
ACR Appendix 3G
04/02/21		495.57KB	Share
ACR Change of Director's Interest Notice
04/02/21		633.49KB	Share
ACR Cleansing Statement
04/02/21		125.57KB	Share
ACR Appendix 2A
03/02/21		327.52KB	Share
ACR Appendix 2A - Share Purchase Plan
02/02/21		327.37KB	Share
ACR Share Purchase Plan Closes Oversubscribed
02/02/21	PRICE SENSITIVE	179.96KB	Share
ACR Results of Extraordinary General Meeting
28/01/21		163.16KB	Share
ACR Change of Director's Interest Notice
15/01/21		249.39KB	Share
ACR Appendix 2A
15/01/21		333.35KB	Share
ACR Acrux Receives FDA Approval - Generic Testosterone Solution
12/01/21	PRICE SENSITIVE	155.5KB	Share
ACR Acrux Ltd Share Purchase Plan Offer Booklet
08/01/21	PRICE SENSITIVE	823.79KB	Share
ACR Ceasing to be a substantial holder
30/12/20		143.27KB	Share
ACR Ceasing to be a substantial holder
29/12/20		135.55KB	Share
ACR Becoming a substantial holder
29/12/20		665.4KB	Share
ACR Cleansing Notice
24/12/20		137.71KB	Share
ACR EGM - Virtual Meeting Online Guide
23/12/20		275.83KB	Share
ACR Notice of Extraordinary General Meeting/Proxy Form
23/12/20		508.15KB	Share
ACR Appendix 2A
23/12/20		326.57KB	Share
ACR Proposed issue of Securities - ACR
21/12/20		24.81KB	Share
ACR Proposed issue of Securities - ACR
21/12/20		34.05KB	Share
ACR Acrux Raises $7.8m Via Placement and Announces SPP
21/12/20	PRICE SENSITIVE	203.34KB	Share
ACR Trading Halt
17/12/20	PRICE SENSITIVE	183.82KB	Share
ACR Change of Director's Interest Notice
15/12/20		251.41KB	Share
ACR Appendix 2A
15/12/20		334.52KB	Share
ACR Change of Director's Interest Notice
17/11/20		344.96KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 5.2¢		Change -0.001(1.89%)		Mkt cap ! $15.11M

Open	High	Low	Value	Volume
5.3¢	5.3¢	5.2¢	$1.664K	31.8K

Buyers (Bids)

No.	Vol.	Price($)
1	146869	5.2¢

Sellers (Offers)

Price($)	Vol.	No.
5.6¢	1974	1

View Market Depth

No.	Vol.	Price($)
1	146869	0.052
2	217490	0.050
1	88000	0.048
1	22222	0.045
1	66000	0.044

Price($)	Vol.	No.
0.056	1974	1
0.058	17257	1
0.060	670	1
0.061	100000	1
0.062	116100	2

Last trade - 15.10pm 01/11/2024 (20 minute delay)

ACR (ASX) Chart

ACRUX LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available